Back to results
US 2008/0306116 A1Published application
Aryloxazole, aryloxadiazole and benzimidazole derivatives
OwnerAndreas D. Christ, Rainer E. Martin +1inventors
InventorsAndreas D. Christ, Rainer E. Martin, Peter Mohr
Life of this patent
Estimating the term…
Abstract
This invention relates to compounds of the formula wherein X is O or NR8, Y is CR7 or N, and R1 to R8 are as defined in the specification, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.
Claims24
A compound of formula I,
- wherein
- X is O or NR8, wherein R8 is hydrogen or C1-7-alkyl;
- Y is CR7or N;
- R1 is selected from the group consisting of ethyl, 2-fluoroethyl, isopropyl and isobutyl;
- R2 is selected from the group consisting of hydrogen, C1-7-alkyl,
- hydroxy, C1-7-alkoxy,
- C3-7-cycloalkyl, —O—C3-7-cycloalkyl,
- halogen, halogen-C1-7-alkyl,
- —C(O)OR9, wherein R9 is C1-7-alkyl,
- —NH—C(O)—R10, wherein R10 is C1-7alkyl, amino,
- pyridyl, imidazolyl, triazolyl, pyrrolyl, phenyl, and
- phenyl substituted by one to three substituents selected from the group consisting of halogen, halogen-C1-7-alkyl and halogen-C1-7-alkoxy;
- R3 is selected from the group consisting of hydrogen, C1-7-alkoxy, amino,
- —NH—C(O)—R11, wherein R11 is C1-7-alkyl,
- —O-benzyl and —O-tetrahydropyranyl;
- or R2 and R3 are bonded to each other to form a ring together with the carbon atoms they are attached to and R2 and R3 together are
- —CH═CH—NH— or —CH═CH—C(CH3)2—O—;
- R4 is selected from the group consisting of hydrogen, halogen, pyridyl and pyrimidyl;
- R5 and R5′ independently from each other are selected from hydrogen or methyl;
- one of R6 or R7 is phenyl or phenyl substituted by one to three substituents selected from the group consisting of
- alogen, halogen-C1-7-alkyl, halogen-C1-7-alkoxy,
- hydroxy, C1-7-alkoxy, hydroxy-C1-7-alkyl, hydroxy-C2-7-alkoxy,
- di-hydroxy-C3-7alkoxy, C1-7-alkoxy-C2-7-alkoxy, C1-7alkoxy-hydroxy-C3-7-alkoxy,
- C3-7-cycloalkyl-C1-7-alkoxy, C3-7-cycloalkoxy,
- C1-7-alkyl, C3-7-cycloalkyl,
- cyano, cyano-C1-7-alkoxy,
- C1-7-alkylamino, di-C1-7-alkylamino, amino-C2-7-alkoxy, amino-C1-7-alkyl,
- C1-7-alkylsulfonyl, —O—C1-7-alkylsulfonyl, C1-7-alkylsulfonyl-C2-7-alkoxy,
- fluorophenyl, pyridyl, tetrazolyl and tetrazolyI-C1-7-alkoxy,
- —C1-7-alkyl-C(O)NR12R13 or —O—C1-7-alkyl-C(O)NR12R13, wherein R11 and R12 are C1-7-alkyl,
- —C1-7-alkyl-C(O)OR14, wherein R14 is C1-7-alkyl, and
- —O—C1-7-alkyl-C(O)OR15, wherein R15 is C1-7-alkyl,
- and the other one of R6 or R7 is hydrogen or absent in case Y is N;
- or R6 and R7 are bonded to each other to form a ring together with the carbon atoms they are attached to and R6 and R7 together are —H═CH—CH═CH—;
- and pharmaceutically acceptable salts thereof.
32 more elements
Dependencies are inferred from the claim text.